24 results on '"Squillace, Rachel M."'
Search Results
2. Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
3. Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
4. Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
5. Supplementary Figure 1 from Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
6. Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
7. Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
8. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
9. Inhibition of muscle differentiation by the novel muscleblind-related protein CHCR
10. Authors’ reply
11. Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery
12. Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
13. Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors
14. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
15. Abstract 3236: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells
16. Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
17. Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
18. Abstract B259: Combined targeting of FGFR2 and mTOR by AP24534 and ridaforolimus results in synergistic antitumor activity in FGFR2‐driven endometrial cancer models
19. Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
20. Expression pattern of muscleblind-like proteins differs in differentiating myoblasts
21. α7 Integrin Mediates Cell Adhesion and Migration on Specific Laminin Isoforms
22. Fragment Growing and LinkingLead to Novel Nanomolar Lactate Dehydrogenase Inhibitors.
23. Comparing two assays for clinical genomic profiling: the devil is in the data.
24. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.